Lifevantage Corp (LFVN) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Lifevantage Corp Do?
LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah. Lifevantage Corp (LFVN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Steven R. Fife and employs approximately 260 people, headquartered in Sandy, Utah. With a market capitalization of $54M, LFVN is one of the notable companies in the Healthcare sector.
Lifevantage Corp (LFVN) Stock Rating — Reduce (April 2026)
As of April 2026, Lifevantage Corp receives a Reduce rating with a composite score of 36.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.LFVN ranks #3,142 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Lifevantage Corp ranks #467 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
LFVN Stock Price and 52-Week Range
Lifevantage Corp (LFVN) currently trades at $4.15. The stock gained $0.13 (3.2%) in the most recent trading session. The 52-week high for LFVN is $16.65, which means the stock is currently trading -75.1% from its annual peak. The 52-week low is $3.90, putting the stock 6.4% above its annual trough. Recent trading volume was 108K shares, suggesting relatively thin trading activity.
Is LFVN Overvalued or Undervalued? — Valuation Analysis
Lifevantage Corp (LFVN) carries a value factor score of 41/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 6.12x, compared to the Healthcare sector average of 23.63x — a discount of 74%. The price-to-book ratio stands at 1.57x, versus the sector average of 2.75x. The price-to-sales ratio is 0.23x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, LFVN trades at 5.05x EV/EBITDA, versus 6.34x for the sector.
Overall, LFVN's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Lifevantage Corp Profitability — ROE, Margins, and Quality Score
Lifevantage Corp (LFVN) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 25.6%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 13.8% versus the sector average of -33.1%.
On a margin basis, Lifevantage Corp reports gross margins of 78.8%, compared to 71.5% for the sector. The operating margin is 4.4% (sector: -66.1%). Net profit margin stands at 3.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 3.6% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
LFVN Debt, Balance Sheet, and Financial Health
Lifevantage Corp has a debt-to-equity ratio of 85.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.03x, indicating strong short-term liquidity.
LFVN has a beta of 1.09, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Lifevantage Corp is 40/100, reflecting average volatility within the normal range for its sector.
Lifevantage Corp Revenue and Earnings History — Quarterly Trend
In TTM 2026, Lifevantage Corp reported revenue of $223M and earnings per share (EPS) of $0.02. Net income for the quarter was $8M. Gross margin was 78.8%. Operating income came in at $10M.
In Q2 2026, Lifevantage Corp reported revenue of $49M and earnings per share (EPS) of $0.02. Net income for the quarter was $276,000. Gross margin was 74.0%. Revenue grew -27.8% year-over-year compared to Q2 2025. Operating income came in at $487,000.
In Q1 2026, Lifevantage Corp reported revenue of $48M and earnings per share (EPS) of $0.17. Net income for the quarter was $2M. Gross margin was 79.5%. Revenue grew 0.7% year-over-year compared to Q1 2025. Operating income came in at $2M.
In FY 2025, Lifevantage Corp reported revenue of $229M and earnings per share (EPS) of $0.80. Net income for the quarter was $10M. Gross margin was 80.4%. Revenue grew 14.2% year-over-year compared to FY 2024. Operating income came in at $12M.
Over the past 8 quarters, Lifevantage Corp has demonstrated a growth trajectory, with revenue expanding from $200M to $223M. Investors analyzing LFVN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
LFVN Dividend Yield and Income Analysis
Lifevantage Corp (LFVN) currently pays a dividend yield of 1.8%. At this yield, a $10,000 investment in LFVN stock would generate approximately $$175.00 in annual dividend income.
LFVN Momentum and Technical Analysis Profile
Lifevantage Corp (LFVN) has a momentum factor score of 12/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.
LFVN vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Lifevantage Corp (LFVN) ranks #467 out of 838 stocks based on the Blank Capital composite score. This places LFVN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing LFVN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LFVN vs S&P 500 (SPY) comparison to assess how Lifevantage Corp stacks up against the broader market across all factor dimensions.
LFVN Next Earnings Date
No upcoming earnings date has been announced for Lifevantage Corp (LFVN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy LFVN? — Investment Thesis Summary
The quantitative profile for Lifevantage Corp suggests caution. Momentum is weak at 12/100, a headwind for near-term performance.
In summary, Lifevantage Corp (LFVN) earns a Reduce rating with a composite score of 36.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LFVN stock.
Related Resources for LFVN Investors
Explore more research and tools: LFVN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LFVN head-to-head with peers: LFVN vs AZN, LFVN vs SLGL, LFVN vs VMD.